$-0.65 EPS Expected for Proteostasis Therapeutics, Inc. (PTI)

March 15, 2018 - By Kenneth Lin

 $ 0.65 EPS Expected for Proteostasis Therapeutics, Inc. (PTI)

Analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to report $-0.65 EPS on March, 29.They anticipate $0.27 EPS change or 71.05 % from last quarter’s $-0.38 EPS. After having $-0.56 EPS previously, Proteostasis Therapeutics, Inc.’s analysts see 16.07 % EPS growth. The stock increased 2.74% or $0.175 during the last trading session, reaching $6.555. About 13.48 million shares traded or 778.75% up from the average. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 66.87% since March 15, 2017 and is downtrending. It has underperformed by 83.57% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $217.05 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

More important recent Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news were published by: Nasdaq.com which released: “Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy …” on March 12, 2018, also Nasdaq.com published article titled: “Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares …”, Globenewswire.com published: “Proteostasis Therapeutics to Present at the Cowen and Company 38th Annual …” on March 07, 2018. More interesting news about Proteostasis Therapeutics, Inc. (NASDAQ:PTI) was released by: Investorplace.com and their article: “Proteostasis Therapeutics Inc (PTI) Soars on Cystic Fibrosis Approval” with publication date: March 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: